MXPA04003689A - Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2. - Google Patents
Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2.Info
- Publication number
- MXPA04003689A MXPA04003689A MXPA04003689A MXPA04003689A MXPA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A MX PA04003689 A MXPA04003689 A MX PA04003689A
- Authority
- MX
- Mexico
- Prior art keywords
- bone
- methods
- pharmaceutical compositions
- administering
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion se refiere a composiciones farmaceuticas y a procedimientos que comprenden agonistas de prostaglandinas, especificamente agonistas selectivos del receptor EP2, que son utiles para potenciar la reparacion y la curacion de los huesos y para restaurar o aumentar la masa osea en vertebrados, particularmente en mamiferos. Los agonistas selectivos del receptor EP2 de la presente invencion son eficaces en el tratamiento de afecciones tales como aquellas en las que el paciente tiene una fractura de union retrasada o sin union, un defecto oseo, fusion espinal, crecimiento oseo hacia el interior, reconstruccion craneofacial o puntos oseos con riesgo de fractura.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33515601P | 2001-11-30 | 2001-11-30 | |
PCT/IB2002/004368 WO2003045371A1 (en) | 2001-11-30 | 2002-10-21 | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04003689A true MXPA04003689A (es) | 2004-07-23 |
Family
ID=23310510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04003689A MXPA04003689A (es) | 2001-11-30 | 2002-10-21 | Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20030166631A1 (es) |
EP (1) | EP1448182A1 (es) |
JP (1) | JP2005513030A (es) |
KR (1) | KR20040063981A (es) |
CN (1) | CN1599605A (es) |
AR (1) | AR037593A1 (es) |
AU (1) | AU2002348948A1 (es) |
BR (1) | BR0214614A (es) |
CA (1) | CA2468494A1 (es) |
GT (1) | GT200200235A (es) |
HN (1) | HN2002000336A (es) |
IL (1) | IL161834A0 (es) |
MX (1) | MXPA04003689A (es) |
NO (1) | NO20042272L (es) |
NZ (1) | NZ532209A (es) |
PA (1) | PA8559601A1 (es) |
PE (1) | PE20030660A1 (es) |
PL (1) | PL370914A1 (es) |
RU (1) | RU2004116318A (es) |
SV (1) | SV2004001417A (es) |
TW (1) | TW200300342A (es) |
UY (1) | UY27556A1 (es) |
WO (1) | WO2003045371A1 (es) |
ZA (1) | ZA200402795B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
EP2422814A1 (en) * | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
ES2564167T3 (es) | 2004-07-08 | 2016-03-18 | Novo Nordisk A/S | Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol |
WO2007017687A2 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
JP2009529051A (ja) * | 2006-03-07 | 2009-08-13 | オステオスクリーン アイピー, エルエルシー | HMGCo−Aレダクターゼ阻害剤による骨および軟骨の強化 |
NZ573964A (en) | 2006-07-28 | 2010-11-26 | Pfizer Prod Inc | isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma |
EP2269611B1 (en) | 2006-11-16 | 2016-03-23 | Gemmus Pharma Inc. | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection |
WO2009025793A2 (en) * | 2007-08-21 | 2009-02-26 | Senomyx, Inc. | Human t2r bitterness receptors and uses thereof |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
FR3034678A1 (fr) * | 2015-04-07 | 2016-10-14 | Geocorail | Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre. |
RU2021103425A (ru) * | 2016-02-12 | 2021-02-25 | Блубёрд Био, Инк. | Композиции, повышающие число копий вектора (чкв), и способы их применения |
US11326183B2 (en) | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4789663A (en) * | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
DE69738613T2 (de) * | 1996-12-20 | 2009-04-30 | Pfizer Inc. | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
-
2002
- 2002-10-21 RU RU2004116318/14A patent/RU2004116318A/ru not_active Application Discontinuation
- 2002-10-21 NZ NZ532209A patent/NZ532209A/en unknown
- 2002-10-21 JP JP2003546873A patent/JP2005513030A/ja not_active Abandoned
- 2002-10-21 BR BR0214614-2A patent/BR0214614A/pt not_active IP Right Cessation
- 2002-10-21 EP EP02781458A patent/EP1448182A1/en not_active Withdrawn
- 2002-10-21 IL IL16183402A patent/IL161834A0/xx unknown
- 2002-10-21 MX MXPA04003689A patent/MXPA04003689A/es not_active Application Discontinuation
- 2002-10-21 PL PL02370914A patent/PL370914A1/xx not_active Application Discontinuation
- 2002-10-21 CA CA002468494A patent/CA2468494A1/en not_active Abandoned
- 2002-10-21 WO PCT/IB2002/004368 patent/WO2003045371A1/en active Application Filing
- 2002-10-21 CN CNA028239385A patent/CN1599605A/zh active Pending
- 2002-10-21 KR KR10-2004-7008309A patent/KR20040063981A/ko not_active Application Discontinuation
- 2002-10-21 AU AU2002348948A patent/AU2002348948A1/en not_active Abandoned
- 2002-11-21 GT GT200200235A patent/GT200200235A/es unknown
- 2002-11-25 TW TW091134181A patent/TW200300342A/zh unknown
- 2002-11-26 PE PE2002001133A patent/PE20030660A1/es not_active Application Discontinuation
- 2002-11-26 US US10/305,649 patent/US20030166631A1/en not_active Abandoned
- 2002-11-27 HN HN2002000336A patent/HN2002000336A/es unknown
- 2002-11-28 UY UY27556A patent/UY27556A1/es not_active Application Discontinuation
- 2002-11-28 AR ARP020104592A patent/AR037593A1/es unknown
- 2002-11-29 SV SV2002001417A patent/SV2004001417A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559601A patent/PA8559601A1/es unknown
-
2004
- 2004-04-13 ZA ZA200402795A patent/ZA200402795B/en unknown
- 2004-06-01 NO NO20042272A patent/NO20042272L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200300342A (en) | 2003-06-01 |
CN1599605A (zh) | 2005-03-23 |
PE20030660A1 (es) | 2003-08-04 |
EP1448182A1 (en) | 2004-08-25 |
JP2005513030A (ja) | 2005-05-12 |
AU2002348948A1 (en) | 2003-06-10 |
PA8559601A1 (es) | 2003-07-28 |
KR20040063981A (ko) | 2004-07-15 |
SV2004001417A (es) | 2004-02-24 |
UY27556A1 (es) | 2003-06-30 |
NO20042272L (no) | 2004-07-28 |
AR037593A1 (es) | 2004-11-17 |
HN2002000336A (es) | 2003-02-10 |
RU2004116318A (ru) | 2005-03-27 |
NZ532209A (en) | 2007-05-31 |
WO2003045371A1 (en) | 2003-06-05 |
US20030166631A1 (en) | 2003-09-04 |
BR0214614A (pt) | 2004-09-14 |
ZA200402795B (en) | 2005-04-13 |
IL161834A0 (en) | 2005-11-20 |
PL370914A1 (en) | 2005-06-13 |
GT200200235A (es) | 2003-06-25 |
CA2468494A1 (en) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04003689A (es) | Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2. | |
SG148037A1 (en) | Fgf variants and methods for use thereof | |
YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
DE602004011083D1 (de) | Orthopädische implantat- und knochenschraubenanordnung | |
WO2005086953A3 (en) | Device and method for fixing bone segments | |
MXPA04001334A (es) | Materiales y metodos para promover la reparacion de tejido nervioso. | |
CA2334257A1 (en) | Treatment of osteoporosis with ep2/ep4 receptor selective agonists | |
HK1053053A1 (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies. | |
AU2003251729A8 (en) | Use of antibodies against flt-1 for the treatment of osteoporosis | |
Tanaka et al. | Use of an injectable complex of β-tricalcium phosphate granules, hyaluronate, and fibroblast growth factor-2 on repair of unstable intertrochanteric fractures | |
MXPA06000460A (es) | Polipeptidos humanos, recombinantes, mejorados de interferon-beta-1b. | |
ZA202100897B (en) | Composition for improved bone fracture healing | |
UA90745C2 (ru) | Способ лечения чрез- и межвертельных переломов бедра у больных преклонного и старческого возраста | |
MD2299F1 (en) | Method of patella fractures osteosynthesis | |
MD1270F1 (en) | Method for treatment of the hand navicular bone pseudarthrosis | |
MD2630G2 (ro) | Metodă de osteosinteză la fracturile periprotetice ale diafizei femurului | |
UA33416A (uk) | Пристрій для остеосинтезу плоских кісток | |
DE60236411D1 (de) | Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe | |
UA34163A (uk) | Спосіб стимулювання остеогенезу при хірургічних втручаннях на кістках щелепи | |
UA36326A (uk) | Пристрій для черезкісткового остеосинтезу поєднаних переломів таранної та п'яткової кісток | |
Nounla et al. | The external transfixation of the knee joint in a case of an open comminuted femoral fracture | |
MD2000F1 (en) | Method of reconstruction of viciously consolidated distal humerus metaphyseal fractures to children | |
UA101594U (ru) | Способ лечения осколочных переломов, ложных суставов и переломов проксимального отдела бедра после металлоостеосинтеза | |
UA31717A (uk) | Спосіб лікування внутрішньосуглобових переломів | |
UA41708A (uk) | Спосіб лікування порушень регенерації кісткової тканини |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |